Genetic Evidence for GLP1R in Heart Failure 03/14/26
Welcome to Cardiology Today â Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and mortality. Key takeaway: Genetic Evidence for GLP1R in Heart Failure.
Article Links:
Article 1: Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes. (European heart journal)
Article 2: Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights. (Heart (British Cardiac Society))
Article 3: Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure. (ESC heart failure)
Article 4: Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair. (European journal of heart failure)
Article 5: Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/
đ Featured Articles
Article 1: Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823519
Summary: The article presents the utility of the new risk factor-weighted clinical likelihood model for estimating the initial pre-test probability of obstructive coronary artery disease. The 2024 European Society of Cardiology guidelines recommend this risk factor-weighted clinical likelihood model as the initial step for individuals with suspected chronic coronary syndromes. This model combines age, sex, symptom characteristics, five clinical risk factors, and coronary calcification data, when available, to provide a numerical estimate of pre-test probability.
Article 2: Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41825942
Summary: A study of 2244 patients with cardiac amyloidosis demonstrated that many present with mildly reduced or reduced ejection fraction, not solely preserved ejection fraction as commonly perceived. The cohort included 557 patients with light chain amyloidosis, 392 with hereditary transthyretin amyloidosis, and 1137 with wild-type transthyretin amyloidosis. Recognizing cardiac amyloidosis across this full spectrum of left ventricular function, from preserved to reduced ejection fraction, is crucial for accurate diagnosis and effective risk stratification.
Article 3: Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41825483
Summary: L. P. 1 R Agonists in Non-Ischaemic Heart Failure. Glucagon-like peptide-one receptor agonists demonstrate existing cardiovascular event reduction in patients with obesity and diabetes, alongside symptomatic and functional benefits in heart failure with preserved ejection fraction. This study employed drug-target Mendelian randomization using genetic variants in the glucagon-like peptide-one receptor locus. The research revealed genetic evidence supporting the efficacy of glucagon-like peptide-one receptor activation in non-ischaemic heart failure. This genetic approach offers insights into mechanisms beyond glycaemic control or weight reduction.
Article 4: Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41825486
Summary: This study, using data from the EuroTR registry, found that coexisting left-sided heart failure phenotypes significantly determine outcomes in patients undergoing tricuspid valve transcatheter edge-to-edge repair for severe tricuspid regurgitation. The research stratified patients based on left ventricular ejection fraction into reduced or mildly reduced heart failure (below 50 percent) and preserved ejection fraction (50 percent or greater). This analysis demonstrated the specific impact of these heart failure subtypes on 2-year all-cause mortality following the repair procedure.
Article 5: Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823981
Summary: This study investigated the cardiovascular-kidney-metabolic syndrome in patients undergoing transcatheter aortic valve implantation. A retrospective analysis of patients from 2011 to 2024 diagnosed and quantified cardiovascular-kidney-metabolic syndrome using a simplified definition. The study established the prevalence of cardiovascular-kidney-metabolic syndrome in this patient population. Furthermore, it demonstrated the significant influence of cardiovascular-kidney-metabolic syndrome on adverse outcomes following transcatheter aortic valve implantation.
đ Transcript
Today’s date is March 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes. The article presents the utility of the new risk factor-weighted clinical likelihood model for estimating the initial pre-test probability of obstructive coronary artery disease. The 2024 European Society of Cardiology guidelines recommend this risk factor-weighted clinical likelihood model as the initial step for individuals with suspected chronic coronary syndromes. This model combines age, sex, symptom characteristics, five clinical risk factors, and coronary calcification data, when available, to provide a numerical estimate of pre-test probability.
Article number two. Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights. A study of 2244 patients with cardiac amyloidosis demonstrated that many present with mildly reduced or reduced ejection fraction, not solely preserved ejection fraction as commonly perceived. The cohort included 557 patients with light chain amyloidosis, 392 with hereditary transthyretin amyloidosis, and 1137 with wild-type transthyretin amyloidosis. Recognizing cardiac amyloidosis across this full spectrum of left ventricular function, from preserved to reduced ejection fraction, is crucial for accurate diagnosis and effective risk stratification.
Article number three. Genetic Evidence for G. L. P. 1 R Agonists in Non-Ischaemic Heart Failure. Glucagon-like peptide-one receptor agonists demonstrate existing cardiovascular event reduction in patients with obesity and diabetes, alongside symptomatic and functional benefits in heart failure with preserved ejection fraction. This study employed drug-target Mendelian randomization using genetic variants in the glucagon-like peptide-one receptor locus. The research revealed genetic evidence supporting the efficacy of glucagon-like peptide-one receptor activation in non-ischaemic heart failure. This genetic approach offers insights into mechanisms beyond glycaemic control or weight reduction.
Article number four. Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair. This study, using data from the EuroTR registry, found that coexisting left-sided heart failure phenotypes significantly determine outcomes in patients undergoing tricuspid valve transcatheter edge-to-edge repair for severe tricuspid regurgitation. The research stratified patients based on left ventricular ejection fraction into reduced or mildly reduced heart failure (below 50 percent) and preserved ejection fraction (50 percent or greater). This analysis demonstrated the specific impact of these heart failure subtypes on 2-year all-cause mortality following the repair procedure.
Article number five. Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation. This study investigated the cardiovascular-kidney-metabolic syndrome in patients undergoing transcatheter aortic valve implantation. A retrospective analysis of patients from 2011 to 2024 diagnosed and quantified cardiovascular-kidney-metabolic syndrome using a simplified definition. The study established the prevalence of cardiovascular-kidney-metabolic syndrome in this patient population. Furthermore, it demonstrated the significant influence of cardiovascular-kidney-metabolic syndrome on adverse outcomes following transcatheter aortic valve implantation.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
risk stratification, mortality, pre-test probability, left-sided heart failure, cardiovascular-kidney-metabolic syndrome, heart failure with reduced ejection fraction, outcomes, glucagon-like peptide-one receptor agonists, European Society of Cardiology guidelines, prevalence, Mendelian randomization, heart failure with preserved ejection fraction, left ventricular function, prognostic relevance, risk factor-weighted clinical likelihood model, genetic evidence, transcatheter aortic valve implantation, tricuspid regurgitation, prognosis, cardiac amyloidosis, chronic coronary syndromes, coronary artery disease, diagnosis, non-ischaemic heart failure, tricuspid valve transcatheter edge-to-edge repair.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow